HeyJaredThe Fellow on Call: The Heme/Onc Podcast
We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion.
- Indexed episodes, last 90 days
- 8
- Latest publication
- Sep 23, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 29, 2026
Latest episodes
Episode 165: CLL Updates Series, Pt. 2 – Relapsed/Refractory in 2026 (opens the original)
Read excerpt
This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy and showing signs of relapse. We cover when relapse actually needs treatment, the history of BTK inhibitor resistance and why BTK mutation testing matters, and how to sequence therapy now that BTK inhibitors and venetoclax have both moved into the frontline. From there we get into venetoclax retreatment, the pirtobrutin
Episode 164: CLL Updates Series, Pt. 1 – Frontline Therapy in 2026 (opens the original)
Read excerpt
This week we kick off a two-part update to our CLL series, covering what has changed in frontline management since our original episodes. Using the case of a 68-year-old man with newly diagnosed, symptomatic CLL, we revisit the essential steps before treatment: confirming an indication to treat, ruling out Richter's transformation, and risk stratification, with the history behind FISH cytogenetics, IGHV status, and the CLL-IPI. We then trace how continuous BTK inhibitors and fixed-duration venet
Episode 163: Head and Neck Cancer Series, Pt. 5 – Recurrent, Relapsed, and Metastatic Disease (opens the original)
Read excerpt
This week the Head and Neck series turns to what happens when local therapy isn't enough — recurrent, relapsed, and metastatic disease. Using the case of a woman with a laryngeal cancer recurrence, we work through the first and most important question (recurrence versus second primary), the workup and biomarkers that steer therapy, local salvage options, the CPS-driven first-line systemic algorithm, second-line and beyond, the distinct world of nasopharyngeal cancer, oligometastatic disease, and
Episode 162: Head and Neck Cancer Series, Pt. 4 – Discussion with Radiation Oncology (opens the original)
Read excerpt
This week the Head and Neck series turns to radiation oncology, with guest Dr. David Palma, a Professor and Radiation Oncologist at the Verspeeten Family Cancer Centre and professor at the Schulich School of Medicine and Dentistry, Western University (London, Ontario). A clinician-scientist who splits his time between clinical-trials research and treating head and neck and lung cancers, David walks us through how radiation actually works and gets planned, the de-escalation question, PET after tr
Episode 161: Career Development Series- Building a Career in Clinical Research (opens the original)
Read excerpt
This week, we are so excited to share the third episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen! This week, we interview Hanny Al-Samkari, MD as he shares his insights on what constit
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.